Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 17/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 16/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 16/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 16/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15746733 | 0.91 | ALDH1A1 (0.38) | HDAC6HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL12515762 | 0.83 | HDAC3 (0.43) | HDAC6HDAC3HDAC1HDAC2MAOB | |
| SCHEMBL1503177 | 0.79 | ALDH1A1 (0.37) | HDAC6HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL1503254 | 0.76 | HDAC3 (0.47) | HDAC6HDAC3HDAC1HDAC2 | |
| SCHEMBL22719912 | 0.76 | KMT2A (0.39) | ALDH1A1MAPK1KMT2AMAOB | |
| SCHEMBL1503192 | 0.75 | ALDH1A1 (0.40) | HDAC6HDAC3HDAC1HDAC2ALDH1A1 | |
| SCHEMBL4448481 | 0.75 | HDAC3 (0.37) | HDAC6HDAC3HDAC1HDAC2MAPK1 | |
| SCHEMBL12444452 | 0.74 | HDAC3 (0.36) | HDAC6HDAC3HDAC1HDAC2MAOB | |
| SCHEMBL1503189 | 0.73 | KMT2A (0.40) | ALDH1A1MAPK1KMT2AMAOB | |
| SCHEMBL30193078 | 0.73 | KMT2A (0.40) | ALDH1A1MAPK1KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | AMBRILIA BIOPHARMA, INC. (CA) | 2011-07-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178120-A1 | HIV INTEGRASE INHIBITORS FROM PYRIDOXINE | PNPO, CCNB1, BLVRB | HDAC6 4827/4885HDAC3 4086/4885HDAC1 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.